These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 37154182)

  • 1. Muscle Ultrasound Abnormalities in Individuals with RYR1-Related Malignant Hyperthermia Susceptibility.
    van den Bersselaar LR; van Alfen N; Kruijt N; Kamsteeg EJ; Fernandez-Garcia MA; Treves S; Riazi S; Yang CY; Malagon I; van Eijk LT; van Engelen BGM; Scheffer GJ; Jungbluth H; Snoeck MMJ; Voermans NC
    J Neuromuscul Dis; 2023; 10(4):541-554. PubMed ID: 37154182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The neuromuscular and multisystem features of RYR1-related malignant hyperthermia and rhabdomyolysis: A study protocol.
    van den Bersselaar LR; Kruijt N; Scheffer GJ; van Eijk L; Malagon I; Buckens S; Custers JA; Helder L; Greco A; Joosten LA; van Engelen BG; van Alfen N; Riazi S; Treves S; Jungbluth H; Snoeck MM; Voermans NC
    Medicine (Baltimore); 2021 Aug; 100(33):e26999. PubMed ID: 34414986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RYR1-Related Rhabdomyolysis: A Spectrum of Hypermetabolic States Due to Ryanodine Receptor Dysfunction.
    Kruijt N; den Bersselaar LV; Snoeck M; Kramers K; Riazi S; Bongers C; Treves S; Jungbluth H; Voermans N
    Curr Pharm Des; 2022; 28(1):2-14. PubMed ID: 34348614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuromuscular symptoms in patients with
    van den Bersselaar LR; Jungbluth H; Kruijt N; Kamsteeg EJ; Fernandez-Garcia MA; Treves S; Riazi S; Malagon I; van Eijk LT; van Alfen N; van Engelen BGM; Scheffer GJ; Snoeck MMJ; Voermans NC
    Brain Commun; 2022; 4(6):fcac292. PubMed ID: 36751502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The histopathological spectrum of malignant hyperthermia and rhabdomyolysis due to RYR1 mutations.
    Knuiman GJ; Küsters B; Eshuis L; Snoeck M; Lammens M; Heytens L; De Ridder W; Baets J; Scalco RS; Quinlivan R; Holton J; Bodi I; Wraige E; Radunovic A; von Landenberg C; Reimann J; Kamsteeg EJ; Sewry C; Jungbluth H; Voermans NC
    J Neurol; 2019 Apr; 266(4):876-887. PubMed ID: 30788618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compound RYR1 heterozygosity resulting in a complex phenotype of malignant hyperthermia susceptibility and a core myopathy.
    Kraeva N; Heytens L; Jungbluth H; Treves S; Voermans N; Kamsteeg E; Ceuterick-de Groote C; Baets J; Riazi S
    Neuromuscul Disord; 2015 Jul; 25(7):567-76. PubMed ID: 25958340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ryanodine receptor mutations in malignant hyperthermia and central core disease.
    McCarthy TV; Quane KA; Lynch PJ
    Hum Mutat; 2000; 15(5):410-7. PubMed ID: 10790202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ryanodine receptor type 1 gene variants in African American men with exertional rhabdomyolysis and malignant hyperthermia susceptibility.
    Sambuughin N; Capacchione J; Blokhin A; Bayarsaikhan M; Bina S; Muldoon S
    Clin Genet; 2009 Dec; 76(6):564-8. PubMed ID: 19807743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis.
    Dlamini N; Voermans NC; Lillis S; Stewart K; Kamsteeg EJ; Drost G; Quinlivan R; Snoeck M; Norwood F; Radunovic A; Straub V; Roberts M; Vrancken AF; van der Pol WL; de Coo RI; Manzur AY; Yau S; Abbs S; King A; Lammens M; Hopkins PM; Mohammed S; Treves S; Muntoni F; Wraige E; Davis MR; van Engelen B; Jungbluth H
    Neuromuscul Disord; 2013 Jul; 23(7):540-8. PubMed ID: 23628358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening of the entire ryanodine receptor type 1 coding region for sequence variants associated with malignant hyperthermia susceptibility in the north american population.
    Sambuughin N; Holley H; Muldoon S; Brandom BW; de Bantel AM; Tobin JR; Nelson TE; Goldfarb LG
    Anesthesiology; 2005 Mar; 102(3):515-21. PubMed ID: 15731587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignant hyperthermia in Japan: mutation screening of the entire ryanodine receptor type 1 gene coding region by direct sequencing.
    Ibarra M CA; Wu S; Murayama K; Minami N; Ichihara Y; Kikuchi H; Noguchi S; Hayashi YK; Ochiai R; Nishino I
    Anesthesiology; 2006 Jun; 104(6):1146-54. PubMed ID: 16732084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes.
    Robinson RL; Brooks C; Brown SL; Ellis FR; Halsall PJ; Quinnell RJ; Shaw MA; Hopkins PM
    Hum Mutat; 2002 Aug; 20(2):88-97. PubMed ID: 12124989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignant hyperthermia susceptibility in patients with exertional rhabdomyolysis: a retrospective cohort study and updated systematic review.
    Kraeva N; Sapa A; Dowling JJ; Riazi S
    Can J Anaesth; 2017 Jul; 64(7):736-743. PubMed ID: 28326467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and Functional Analysis of RYR1 Variants in a Family with a Suspected Myopathy and Associated Malignant Hyperthermia.
    Schiemann AH; Roesl C; Pollock N; Langton E; Bulger T; Stowell KM
    J Neuromuscul Dis; 2020; 7(1):51-60. PubMed ID: 31903994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation screening in the ryanodine receptor 1 gene (RYR1) in patients susceptible to malignant hyperthermia who show definite IVCT results: identification of three novel mutations.
    Rueffert H; Olthoff D; Deutrich C; Meinecke CD; Froster UG
    Acta Anaesthesiol Scand; 2002 Jul; 46(6):692-8. PubMed ID: 12059893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic variation in RYR1 and malignant hyperthermia phenotypes.
    Carpenter D; Robinson RL; Quinnell RJ; Ringrose C; Hogg M; Casson F; Booms P; Iles DE; Halsall PJ; Steele DS; Shaw MA; Hopkins PM
    Br J Anaesth; 2009 Oct; 103(4):538-48. PubMed ID: 19648156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical model systems of ryanodine receptor 1-related myopathies and malignant hyperthermia: a comprehensive scoping review of works published 1990-2019.
    Lawal TA; Wires ES; Terry NL; Dowling JJ; Todd JJ
    Orphanet J Rare Dis; 2020 May; 15(1):113. PubMed ID: 32381029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mild clinical and histopathological features in patients who carry the frequent and causative malignant hyperthermia RyR1 mutation p.Thr2206Met.
    Rueffert H; Wehner M; Ogunlade V; Meinecke C; Schober R
    Clin Neuropathol; 2009; 28(6):409-16. PubMed ID: 19919814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetics of malignant hyperthermia.
    Brandom BW
    ScientificWorldJournal; 2006 Dec; 6():1722-30. PubMed ID: 17195870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mice expressing T4826I-RYR1 are viable but exhibit sex- and genotype-dependent susceptibility to malignant hyperthermia and muscle damage.
    Yuen B; Boncompagni S; Feng W; Yang T; Lopez JR; Matthaei KI; Goth SR; Protasi F; Franzini-Armstrong C; Allen PD; Pessah IN
    FASEB J; 2012 Mar; 26(3):1311-22. PubMed ID: 22131268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.